Recent advances in liposomes and nanoparticles as drug carriers for drug delivery

Acta Academiae Medicinae Sinicae

Volumn 28, Issue 4, 2006, Pages 583-589

  Liu, Yang ^a   Lü, Wan Liang ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Drug delivery system; Liposomes; Nanoparticles

Indexed keywords

CALCIMYCIN; CISPLATIN; DRUG CARRIER; LIPOSOME; MACROGOL; MITOPODOZIDE; NANOCAPSULE; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; VACCINE;

ARTICLE; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOXICITY; IN VIVO STUDY; MULTIDRUG RESISTANCE;

DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOPARTICLES; VACCINES;

EID: 33749870632     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Markman M, Gordon AN, McGuire WP, et al. Liposomal anthracycline treatment for ovarian cancer. Semin Oncol, 2004, 31(6 Suppl 13):91-105.
2. Krown SE, Northfelt DW, Osoba D, et al. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol, 2004, 31(6 Suppl 13):36-52.
3. Felnerova D, Viret JF, Gluck R. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotech, 2004, 15:518-529.
4. Barenholz Y. Liposome application: problems and prospects. Curr Opin Collo Interf Sci, 2001, 6(1):66-77.
5. Chiu GN, Abraham SA, Ickenstein LM, et al. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release, 2005, 104(2):271-288.
6. Abraham SA, Edwards K, Karlsson G, et al. An evaluation of transmembrane ion gradient-mediated encapsulation of topotecan within Iiposomes. J Control Release, 2004, 96(3):449-461.
7. Prabhananda BS, Kombrabail MH. Evidence for dimer participation and evidence against channel mechanism in A23187-mediated monovalent metal ion transport across phospholipid vesicular membrane. Biophys J, 1998, 75:1749-1758.
8. Kim ES, Lu C, Khuri FR, et al. A phase II study of stealth cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer, 2001, 34(3):427-432.
9. Harrington KJ, Lewanski CR, Northcote AD, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol, 2001, 12 (4):493-496.
10. Bandak S, Goren D, Horowitz A, et al. Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anti Cancer Drugs, 1999, 10(10):911-920.
11. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 2001, 70(1-2):1-20.
12. Torchilin VP. Polymer-coated long-circulating microparticulate pharmaceuticals. J Microencapsul, 1998, 15(1):1-19.
13. Belsito S, Bartucci R, Montesano C, et al. Molecular and mesoscopic properties of hydrophilic polymer-grafted phospholipids mixed with phosphatidylcholine in aqueous dispersion: interaction of dipalmitoyl N-poly (ethylene glycol) phosphat idylethanolamine with dipalmitoylphosphatidylcholine studied by spectrophotometry and spin-label electron spin resonance. Biophys J, 2000, 78(3):1420-1430.
14. Peracchia MT, Harnisch S, Pinto-Alphandary H, et al. Visualization of in vitro protein-rejecting properties of PEGylated stealth (R) polycyanoacrylate nanoparticles. Biomaterials, 1999, 20(14):1269-1275.
15. Ishida T, Okada Y, Kobayashi T, et al. Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm, 2006, 309(1-2):94-100.
16. Felgner PL, Gadeck T, Holen M, et al. Lipofectin: a highly efficient lipid-mediated DNA transfection procedure. Proc Natl Acad Sci USA, 1987, 84(21):7413-7417.
17. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today, 2006, 11:67-73.
18. Zhang C, Tang N, Liu XJ, et al. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release, 2006, 112(2):229-239.
19. Matsumura Y, Maeda A. A new concept for macromolecular therapies in cancer chemotherapy: mechanisms of tumortropic accumulation of proteins and the antitumor agents smancs. Cancer Res, 1986, 46(12 Pt 1):6387-6392.
20. Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res, 2001, 7(2):243-254.
21. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer, 2000, 83(2):232-238.
22. Ewer MS, Martin FJ, Henderson C, et al. Cardiac safety of liposomal anthracyclines. Semin Oncol, 2004, 31 (6 Suppl 13):161-181.
23. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002, 346 (4):235-242.
24. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001, 344(11):783-792.
25. Lopes de Menezes DE, Pilarski LM, Belch AR, et al. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta, 2000, 1466:205-220.
26. Maruyama K, Ishida O, Takizawa T. Possibility of active targeting to tumor tissues with liposomes. Adv Drug Deliv Rev, 1999, 40(1-2):89-102.
27. Xiong XB, Huang Y, Lu WL, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release, 2005, 107(2):262-275.
28. Anna C, Simcha EC, Jacqueline Z, et al. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2. Clin Cancer Res, 1999, 5(3):687-693.
29. Potineni A, Lynn DM, Langer R, et al. Poly (ethylene oxide)-modified poly (β-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J Control Release, 2003, 86(2-3):223-234.
30. Chen Q, Tong S, Dewhirst MW, et al. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther, 2004, 3(10):1311-1317.
31. Hirsch LR, Stafford RJ, Bankson JA. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA, 2003, 100(23): 13549-13554.
32. Roy I, Ohulchanskyy TY, Pudavar HE. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc, 2003, 125(26):7860-7865.
33. 2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. J Control Release, 2006, 112(2):186-198.
34. Li X, Lu WL, Liang GW, et al. Effect of stealthy liposomal topotecan plus amlodipine on the multi-drug resistant leukaemia cells in vitro and xenograft in mice. Eur J Clin Invest, 2006, 36(6): 409-418.
35. Medina OP, Kairemo K, Valtanen H, et al. Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide. Anticancer Res, 2005, 25(1A):33-42.
36. Winter PM, Lanza GM, Wickline SA. Molecular imaging of angiogenesis in early-stage atherosclerosis with αvβ3-integrin-targeted nanoparticles. Circulation, 2003, 108(18): 2270-2274.
37. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res, 2003, 63(18):5838-5843.
38. Kreuter J, Petrov VE, Kharkevich DA, et al. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood brain barrier using surfactant-coated nanoparticles. J Control Release, 1997, 49(1):81-87.
39. Gulyaev AE, Gelperina SE, Skidan IN, et al. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res, 1999, 16(10):1564-1619.
40. Shi N, Zhang Y, Zhu C, et al. Brain-specific expression of an exogenous gene after i. v. administration. Proc Natl Acad Sci, 2001, 98 (22):12754-12759.
41. Noble CO, Kirpotin DB, Hayes ME, et al. Development of ligand targeted liposomes for cancer therapy. Expert Opin Ther Targets, 2004, 8(4):335-353.
42. Jiang F, Lilge L, Grenier J, et al. Photodynamic therapy of U87 human glioma in nude rat using liposome-delivered photo-frin. Lasers Surg Med, 1998, 22(2):74-80.
43. Aoki H, Kakinuma K, Morita K, et al. Therapeutic efficacy of targeting chemotherapy using local hyperthermia and thermosensitive liposome: evaluation of drug distribution in a rat glioma model. Int J Hypertherm, 2004, 20(6):595-605.
44. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol, 2004, 68(1):1-9.
45. Elaine ML, Simon LM, Gary GL, et al. Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin. Pharm Res, 2004, 21(9):1545-1553.
46. Ma ZS, Lim TM, Lim LY. Pharmacological activity of peroral chitosan insulin nanoparticles in diabetic rats. Int J Pharm, 2005, 293(1-2):271-280.
47. Goto T, Morishita M, Nishimura K, et al. Novel mucosal insulin delivery systems based on fusogenic liposomes. Pharm Res, 2006, 23(2):384-391.
48. Singh SK, Bisen PS. Adjuvanticity of stealth liposomes on the immunogenicity of synthetic gp41 epitope of HIV-1. Vaccine, 2006, 24(19):4161-4166.
49. Mishra D, Dubey V, Asthana A, et al. Elastic liposomes mediated transcutaneous immunization against hepatitis B. Vaccine, 2006, 24(22):4847-4855.